Endothelial Oxidative Stress and Inflammation:Mechanisms and Human Studies

内皮氧化应激和炎症:机制和人体研究

基本信息

  • 批准号:
    8209219
  • 负责人:
  • 金额:
    $ 39.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-01 至 2015-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic heart failure (CHF) is a systemic inflammatory disease characterized by endothelial dysfunction and neurohormonal activation. Patients with chronic heart failure (CHF) consume a large percentage of health care resources as they are frequently hospitalized for acute decompensated heart failure (ADHF) based on clinical evidence of venous congestion. Accumulating evidence suggests that (i) venous congestion is a major predictor of morbidity and mortality in ADHF; and (ii) venous congestion begins to occur weeks before symptoms worsen resulting in a need for urgent in-hospital therapy. Despite this clinical evidence suggesting a role for venous congestion in the pathophysiology of ADHF, the biomechanically-driven effects of venous congestion on the vascular endothelium (the largest endocrine/paracrine organ of the body) and on neurohormonal activation remain unexplored. Our preliminary data using a novel, safe method of venous endothelial sampling coupled with analysis of protein and gene expression, indicate that: (i) clinical congestion, in patients hospitalized for ADHF, is associated with endothelial activation of the oxidative/inflammatory programs; and, mechanistically, (ii) that experimental congestion, in normal subjects, is sufficient to promote endothelial and neurohormonal activation. The central hypothesis of the proposed research is that venous congestion, in patients with CHF, acts as an independent oxidative/inflammatory stimulus which modulates key genetic regulatory events related to endothelial and neurohormonal activation, and, thereby, to the development and the resolution of ADHF. We propose to investigate this hypothesis using a two-pronged design which will allow us to study "volume- sensitive" genes and proteins, and global gene expression in endothelial cells, as well as neurohormonal activity in plasma in response to both (i) acute experimental congestion among n=24 compensated, euvolemic CHF patients with no recent history of ADHF, as well as among n=24 compensated patients with recent history of ADHF (Aim 1); and, conversely (ii) acute therapeutic decongestion, by "high" volume vs. "standard" volume ulltrafiltration, among n=48 patients hospitalized for ADHF with clinical evidence of venous congestion (Aim 2). In 2007, the NIH identified inflammation as "a key area of public health in need of broad-based collaborative research". If successful, our studies (i) will model the biomechanically-driven pathways that initiate and sustain inflammation in veins and thereby contribute to the clinical transition from compensation to acute decompensation in CHF; and, on the other side of the equation, (ii) will uncover those anti-oxidant/anti- inflammatory cascades that contribute to the prevention and/or resolution of ADHF. Overall, our data may provide a strong rationale for future studies that will use a molecular-based approach, in the unique individual, for the prevention and treatment of ADHF. PUBLIC HEALTH RELEVANCE: Chronic heart failure (CHF) is a major health problem; a systemic rather than only cardiac disorder characterized by vascular and neurohormonal derangement. Patients with CHF are responsible for consuming a large percentage of the health care resources as they are frequent hospitalized for acute decompensation. The results of this study will help elucidate the vascular and neurohormonal events that sustain clinical compensation and/or promote resolution of decompensation in the unique CHF patient, thus paving the way to more predictive and personalized medicine.
描述(由申请方提供):慢性心力衰竭(CHF)是一种全身性炎症性疾病,其特征为内皮功能障碍和神经激素激活。慢性心力衰竭(CHF)患者消耗了很大比例的医疗资源,因为他们经常因静脉充血的临床证据导致急性失代偿性心力衰竭(ADHF)而住院。越来越多的证据表明:(i)静脉充血是ADHF发病率和死亡率的主要预测因素;(ii)静脉充血在症状恶化导致需要紧急住院治疗前数周开始发生。尽管该临床证据表明静脉充血在ADHF的病理生理学中的作用,但静脉充血对血管内皮(身体最大的内分泌/旁分泌器官)和神经激素激活的生物力学驱动效应仍未探索。 我们的初步数据使用一种新的,安全的静脉内皮取样方法,结合蛋白质和基因表达的分析,表明:(i)临床充血,在ADHF住院患者,与内皮细胞激活的氧化/炎症程序;和,机械,(ii)实验充血,在正常受试者,足以促进内皮细胞和神经激素的激活。拟议研究的中心假设是,CHF患者的静脉充血作为一种独立的氧化/炎症刺激,调节与内皮和神经激素激活相关的关键遗传调节事件,从而调节ADHF的发展和解决。 我们建议使用双管齐下的设计来研究这一假设,这将使我们能够研究“容量敏感性”基因和蛋白质,以及内皮细胞中的整体基因表达,以及血浆中响应于以下两者的神经激素活性:(i)n=24例代偿性、正常血容量性CHF患者中的急性实验性充血,这些患者近期没有ADHF病史,以及n=24例有ADHF近期病史的代偿患者(目标1);相反,(ii)急性治疗性缓解,通过“高”容量与“标准”容量超滤,n=48例因ADHF住院且有静脉充血临床证据的患者(目标2)。 2007年,NIH将炎症确定为“需要广泛合作研究的公共卫生关键领域”。如果成功,我们的研究(i)将模拟生物力学驱动的途径,这些途径在静脉中引发和维持炎症,从而有助于CHF从代偿到急性失代偿的临床转变;并且,在等式的另一边,(ii)将揭示有助于预防和/或解决ADHF的抗氧化/抗炎级联反应。总体而言,我们的数据可能为未来的研究提供强有力的理论基础,这些研究将在独特的个体中使用基于分子的方法来预防和治疗ADHF。 公共卫生相关性:慢性心力衰竭(CHF)是一个主要的健康问题;一个系统性的,而不仅仅是心脏疾病的特点是血管和神经激素紊乱。CHF患者因急性失代偿而频繁住院,因此消耗了很大比例的医疗保健资源。这项研究的结果将有助于阐明维持临床代偿和/或促进独特CHF患者失代偿的解决的血管和神经激素事件,从而为更具预测性和个性化的药物铺平道路。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAOLO C COLOMBO其他文献

PAOLO C COLOMBO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAOLO C COLOMBO', 18)}}的其他基金

Cardiac Lipotoxicity and Ceramide Metabolism in Heart Failure
心力衰竭中的心脏脂肪毒性和神经酰胺代谢
  • 批准号:
    9039132
  • 财政年份:
    2013
  • 资助金额:
    $ 39.85万
  • 项目类别:
Endothelial Oxidative Stress and Inflammation:Mechanisms and Human Studies
内皮氧化应激和炎症:机制和人体研究
  • 批准号:
    7783700
  • 财政年份:
    2010
  • 资助金额:
    $ 39.85万
  • 项目类别:
Endothelial Oxidative Stress and Inflammation:Mechanisms and Human Studies
内皮氧化应激和炎症:机制和人体研究
  • 批准号:
    8625327
  • 财政年份:
    2010
  • 资助金额:
    $ 39.85万
  • 项目类别:
Endothelial Oxidative Stress and Inflammation:Mechanisms and Human Studies
内皮氧化应激和炎症:机制和人体研究
  • 批准号:
    8015574
  • 财政年份:
    2010
  • 资助金额:
    $ 39.85万
  • 项目类别:
Endothelial Oxidative Stress and Inflammation:Mechanisms and Human Studies
内皮氧化应激和炎症:机制和人体研究
  • 批准号:
    8440706
  • 财政年份:
    2010
  • 资助金额:
    $ 39.85万
  • 项目类别:
ENDOTHELIAL CELL ACTIVATION AND DECOMPENSATION IN CHF
CHF 中的内皮细胞激活和失代偿
  • 批准号:
    6594790
  • 财政年份:
    2002
  • 资助金额:
    $ 39.85万
  • 项目类别:
ENDOTHELIAL CELL ACTIVATION AND DECOMPENSATION IN CHF
CHF 中的内皮细胞激活和失代偿
  • 批准号:
    6645478
  • 财政年份:
    2002
  • 资助金额:
    $ 39.85万
  • 项目类别:
ENDOTHELIAL CELL ACTIVATION AND DECOMPENSATION IN CHF
CHF 中的内皮细胞激活和失代偿
  • 批准号:
    6759997
  • 财政年份:
    2002
  • 资助金额:
    $ 39.85万
  • 项目类别:
ENDOTHELIAL CELL ACTIVATION AND DECOMPENSATION IN CHF
CHF 中的内皮细胞激活和失代偿
  • 批准号:
    7061751
  • 财政年份:
    2002
  • 资助金额:
    $ 39.85万
  • 项目类别:
ENDOTHELIAL CELL ACTIVATION AND DECOMPENSATION IN CHF
CHF 中的内皮细胞激活和失代偿
  • 批准号:
    6888157
  • 财政年份:
    2002
  • 资助金额:
    $ 39.85万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 39.85万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 39.85万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 39.85万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 39.85万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 39.85万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 39.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了